Urothelial Carcinoma Treatment Market, 2012 to 2023
Market Outline: Urothelial Carcinoma Treatment Market
Urothelial carcinoma is also called as transitional cell carcinoma. Urothelial carcinoma is a type of cancer that occurs in the urinary system and it is most common type of bladder cancer of the ureter, urachus and urethra. Urothelial cell carcinoma starts from transitional epithelium. Potential signs in recognising the urothelial carcinoma include blood in urine, persistent back pain and painful urination. Generally, urothelial cell carcinoma is diagnosed using the blood tests and scanning. Treatment may include anticancer drugs, antibacterials to reduce or stop the growth of cancer cells and other treatments such as radiotherapy or nephroureterectomy are indicated.
Market Dynamics: Urothelial Carcinoma Treatment Market
Urothelial carcinoma treatment market is driven by the increase in global prevalence of the bladder cancer and emergence of potential diagnostics for identifying bladder cancer. Furthermore, increase funding for R&D activities to develop new cancer therapies and growing awareness regarding early diagnosis of cancer as a result of awareness programs or other initiatives by government and non-government organizations are expected to boost the urothelial carcinoma treatment market over the forecast period. However, high cost of R&D for development of new drugs and presence of generic drugs in the market are expected to hamper the market revenue growth during the forecast period.
Market Scope: Urothelial Carcinoma Treatment Market
Global urothelial carcinoma treatment market is segmented based on type of treatment, and distribution channel
Based on treatment, it segmented into
Immunotherapy
Radiotherapy
Chemotherapy
Others
Based on distribution channel, it is segmented into
Hospital Pharmacies
Retail Pharmacies
Others
Market Summary: Urothelial Carcinoma Treatment Market
Global urothelial carcinoma treatment market growth is driven by increase in global prevalence rate of bladder cancer. According to World Cancer Research Fund International, bladder cancer is the ninth most common cancer in the world and in the year 2012 - 430,000 new cases were diagnosed. The market has many large players and actively developing and launching of new products related to urothelial carcinoma treatment. For instance, in March 2017, Bavarian Nordic A/S collaborated with F.Hoffmann-La Roche Ltd to evaluate the Tecentriq and CV301 drugs in urothelial cancer treatment. Furthermore, promising pipeline drugs for treatment of urothelial carcinoma such as B-701 (in phase 2 clinical trials by BioClin Therapeutics, FGFR-3 Antibody (By Eli Lilly and Company in phase 1 clinical trials) are expected to boost future revenue forecasts.
Region Analysis: Urothelial Carcinoma Treatment Market
Geographically, urothelial carcinoma treatment market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America expected to grow at significant rates owing to growing prevalence of bladder cancer, increase in awareness and well-established healthcare infrastructure. American Cancer Society estimates that, about 79,030 new cases of bladder cancer in 2017 in U.S. alone. Europe region expected to grow at notable rates owing to the factors such as growing awareness related to early diagnosis of cancer and developed healthcare infrastructure coupled with prevalence rates of urothelial cancer. Asia Pacific region is expected exhibit significant growth opportunity owing to developing healthcare infrastructure and low R&D costs.
Market Participants: Urothelial Carcinoma Treatment Market
Some of the players in Market are GlaxoSmithKline plc (U.K.), Genentech, Inc. (U.S.), Novartis AG (Switzerland), Dendreon (U.S.), Merck KGaA (Germany), Eisai Co. (Japan), Sanofi S.A. (France), and Bristol-Myers Squibb (U.S.) to name a few
Notable Market Developments: Urothelial carcinoma Treatment Market
In May 2017, U.S. Food and Drug Administration approved Sereno Inc.’s (E. Merck KG) BAVENCIO (avelumab) for the treatment of urothelial carcinoma.
In February 2017, U.S. FDA has approved Bristol-Mayer Squibb Company’s OPDIVO (Nivolumab) for the treatment of urothelial carcinoma.
Urothelial carcinoma is also called as transitional cell carcinoma. Urothelial carcinoma is a type of cancer that occurs in the urinary system and it is most common type of bladder cancer of the ureter, urachus and urethra. Urothelial cell carcinoma starts from transitional epithelium. Potential signs in recognising the urothelial carcinoma include blood in urine, persistent back pain and painful urination. Generally, urothelial cell carcinoma is diagnosed using the blood tests and scanning. Treatment may include anticancer drugs, antibacterials to reduce or stop the growth of cancer cells and other treatments such as radiotherapy or nephroureterectomy are indicated.
Market Dynamics: Urothelial Carcinoma Treatment Market
Urothelial carcinoma treatment market is driven by the increase in global prevalence of the bladder cancer and emergence of potential diagnostics for identifying bladder cancer. Furthermore, increase funding for R&D activities to develop new cancer therapies and growing awareness regarding early diagnosis of cancer as a result of awareness programs or other initiatives by government and non-government organizations are expected to boost the urothelial carcinoma treatment market over the forecast period. However, high cost of R&D for development of new drugs and presence of generic drugs in the market are expected to hamper the market revenue growth during the forecast period.
Market Scope: Urothelial Carcinoma Treatment Market
Global urothelial carcinoma treatment market is segmented based on type of treatment, and distribution channel
Based on treatment, it segmented into
Immunotherapy
Radiotherapy
Chemotherapy
Others
Based on distribution channel, it is segmented into
Hospital Pharmacies
Retail Pharmacies
Others
Market Summary: Urothelial Carcinoma Treatment Market
Global urothelial carcinoma treatment market growth is driven by increase in global prevalence rate of bladder cancer. According to World Cancer Research Fund International, bladder cancer is the ninth most common cancer in the world and in the year 2012 - 430,000 new cases were diagnosed. The market has many large players and actively developing and launching of new products related to urothelial carcinoma treatment. For instance, in March 2017, Bavarian Nordic A/S collaborated with F.Hoffmann-La Roche Ltd to evaluate the Tecentriq and CV301 drugs in urothelial cancer treatment. Furthermore, promising pipeline drugs for treatment of urothelial carcinoma such as B-701 (in phase 2 clinical trials by BioClin Therapeutics, FGFR-3 Antibody (By Eli Lilly and Company in phase 1 clinical trials) are expected to boost future revenue forecasts.
Region Analysis: Urothelial Carcinoma Treatment Market
Geographically, urothelial carcinoma treatment market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America expected to grow at significant rates owing to growing prevalence of bladder cancer, increase in awareness and well-established healthcare infrastructure. American Cancer Society estimates that, about 79,030 new cases of bladder cancer in 2017 in U.S. alone. Europe region expected to grow at notable rates owing to the factors such as growing awareness related to early diagnosis of cancer and developed healthcare infrastructure coupled with prevalence rates of urothelial cancer. Asia Pacific region is expected exhibit significant growth opportunity owing to developing healthcare infrastructure and low R&D costs.
Market Participants: Urothelial Carcinoma Treatment Market
Some of the players in Market are GlaxoSmithKline plc (U.K.), Genentech, Inc. (U.S.), Novartis AG (Switzerland), Dendreon (U.S.), Merck KGaA (Germany), Eisai Co. (Japan), Sanofi S.A. (France), and Bristol-Myers Squibb (U.S.) to name a few
Notable Market Developments: Urothelial carcinoma Treatment Market
In May 2017, U.S. Food and Drug Administration approved Sereno Inc.’s (E. Merck KG) BAVENCIO (avelumab) for the treatment of urothelial carcinoma.
In February 2017, U.S. FDA has approved Bristol-Mayer Squibb Company’s OPDIVO (Nivolumab) for the treatment of urothelial carcinoma.
1. EXECUTIVE SUMMARY
2. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET INTRODUCTION
2.1. Global Urothelial Carcinoma Treatment Market – Taxonomy
2.2. Global Urothelial Carcinoma Treatment Market –Definitions
2.2.1. Therapy
2.2.2. Distribution Channel
3. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Urothelial Carcinoma Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Urothelial Carcinoma Treatment Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Urothelial Carcinoma Treatment Market – Product Innovations
4. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Therapy Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Immunotherapy
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Radiotherapy
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Chemotherapy
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Others
5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
6. MARKET OPPORTUNITY ANALYSIS GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
7. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. North America
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.5.3. Market Opportunity Analysis
7.6. Global Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Region, 2017 – 2023
8. NORTH AMERICA UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.2. Immunotherapy
8.1.3. Radiotherapy
8.1.4. Chemotherapy
8.1.5. Others
8.1.6. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.1.6.1. Hospital Pharmacies
8.1.6.2. Retail Pharmacies
8.1.6.3. Others
8.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.1.7.1. U.S.
8.1.7.2. Canada
8.1.8. North America Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel and Country, 2017 – 2023
8.1.9. North America Urothelial Carcinoma Treatment Market Dynamics – Trends
9. EUROPE UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.2. Immunotherapy
9.1.3. Radiotherapy
9.1.4. Chemotherapy
9.1.5. Others
9.1.6. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.6.1. Hospital Pharmacies
9.1.6.2. Retail Pharmacies
9.1.6.3. Others
9.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.7.1. Germany
9.1.7.2. UK
9.1.7.3. France
9.1.7.4. Spain
9.1.7.5. Italy
9.1.7.6. Russia
9.1.7.7. Poland
9.1.7.8. Rest of Europe
9.1.8. Europe Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Country, 2017 – 2023
9.1.9. Europe Urothelial Carcinoma Treatment Market Dynamics – Trends
10. ASIA-PACIFIC UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2. Immunotherapy
10.1.3. Radiotherapy
10.1.4. Chemotherapy
10.1.5. Others
10.1.6. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.6.1. Hospital Pharmacies
10.1.6.2. Retail Pharmacies
10.1.6.3. Others
10.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
10.1.7.1. Japan
10.1.7.2. China
10.1.7.3. India
10.1.7.4. ASEAN
10.1.7.5. Australia & New Zealand
10.1.7.6. Rest of Asia-Pacific
10.1.8. Asia-Pacific Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Country, 2017 – 2023
10.1.9. Asia-Pacific Urothelial Carcinoma Treatment Market Dynamics – Trends
11. LATIN AMERICA UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2. Immunotherapy
11.1.3. Radiotherapy
11.1.4. Chemotherapy
11.1.5. Others
11.1.6. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.6.1. Hospital Pharmacies
11.1.6.2. Retail Pharmacies
11.1.6.3. Others
11.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.7.1. Brazil
11.1.7.2. Mexico
11.1.7.3. Argentina
11.1.7.4. Venezuela
11.1.7.5. Rest of Latin America
11.1.8. Latin America Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Country, 2017 – 2023
11.1.9. Latin America Urothelial Carcinoma Treatment Market Dynamics – Trends
12. MIDDLE EAST AND AFRICA UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.3. Immunotherapy
12.1.4. Radiotherapy
12.1.5. Chemotherapy
12.1.6. Others
12.1.7. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.7.1. Hospital Pharmacies
12.1.7.2. Retail Pharmacies
12.1.7.3. Others
12.1.8. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.8.1. Gulf Cooperation Council (GCC) Countries
12.1.8.2. Israel
12.1.8.3. South Africa
12.1.8.4. Rest of MEA
12.1.9. MEA Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Country, 2017 – 2023
12.1.10. MEA Urothelial Carcinoma Treatment Market Dynamics – Trends
13. COMPETITION LANDSCAPE
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Ferring B.V. (Switzerland)
13.2.2. Azanta A/S (Denmark)
13.2.3. Novartis AG (Switzerland)
13.2.4. GlaxoSmithKline plc (U.K.)
13.2.5. AstraZeneca plc (U.K.)
13.2.6. Pfizer, Inc. (U.S.)
13.2.7. Bayer AG (Germany)
14. RESEARCH METHODOLOGY
15. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET INTRODUCTION
2.1. Global Urothelial Carcinoma Treatment Market – Taxonomy
2.2. Global Urothelial Carcinoma Treatment Market –Definitions
2.2.1. Therapy
2.2.2. Distribution Channel
3. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Urothelial Carcinoma Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Urothelial Carcinoma Treatment Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Urothelial Carcinoma Treatment Market – Product Innovations
4. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Therapy Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Immunotherapy
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Radiotherapy
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Chemotherapy
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Others
5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
6. MARKET OPPORTUNITY ANALYSIS GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
7. GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. North America
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.5.3. Market Opportunity Analysis
7.6. Global Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Region, 2017 – 2023
8. NORTH AMERICA UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.2. Immunotherapy
8.1.3. Radiotherapy
8.1.4. Chemotherapy
8.1.5. Others
8.1.6. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.1.6.1. Hospital Pharmacies
8.1.6.2. Retail Pharmacies
8.1.6.3. Others
8.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.1.7.1. U.S.
8.1.7.2. Canada
8.1.8. North America Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel and Country, 2017 – 2023
8.1.9. North America Urothelial Carcinoma Treatment Market Dynamics – Trends
9. EUROPE UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.2. Immunotherapy
9.1.3. Radiotherapy
9.1.4. Chemotherapy
9.1.5. Others
9.1.6. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.6.1. Hospital Pharmacies
9.1.6.2. Retail Pharmacies
9.1.6.3. Others
9.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.7.1. Germany
9.1.7.2. UK
9.1.7.3. France
9.1.7.4. Spain
9.1.7.5. Italy
9.1.7.6. Russia
9.1.7.7. Poland
9.1.7.8. Rest of Europe
9.1.8. Europe Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Country, 2017 – 2023
9.1.9. Europe Urothelial Carcinoma Treatment Market Dynamics – Trends
10. ASIA-PACIFIC UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2. Immunotherapy
10.1.3. Radiotherapy
10.1.4. Chemotherapy
10.1.5. Others
10.1.6. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.6.1. Hospital Pharmacies
10.1.6.2. Retail Pharmacies
10.1.6.3. Others
10.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
10.1.7.1. Japan
10.1.7.2. China
10.1.7.3. India
10.1.7.4. ASEAN
10.1.7.5. Australia & New Zealand
10.1.7.6. Rest of Asia-Pacific
10.1.8. Asia-Pacific Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Country, 2017 – 2023
10.1.9. Asia-Pacific Urothelial Carcinoma Treatment Market Dynamics – Trends
11. LATIN AMERICA UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2. Immunotherapy
11.1.3. Radiotherapy
11.1.4. Chemotherapy
11.1.5. Others
11.1.6. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.6.1. Hospital Pharmacies
11.1.6.2. Retail Pharmacies
11.1.6.3. Others
11.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.7.1. Brazil
11.1.7.2. Mexico
11.1.7.3. Argentina
11.1.7.4. Venezuela
11.1.7.5. Rest of Latin America
11.1.8. Latin America Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Country, 2017 – 2023
11.1.9. Latin America Urothelial Carcinoma Treatment Market Dynamics – Trends
12. MIDDLE EAST AND AFRICA UROTHELIAL CARCINOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.3. Immunotherapy
12.1.4. Radiotherapy
12.1.5. Chemotherapy
12.1.6. Others
12.1.7. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.7.1. Hospital Pharmacies
12.1.7.2. Retail Pharmacies
12.1.7.3. Others
12.1.8. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.8.1. Gulf Cooperation Council (GCC) Countries
12.1.8.2. Israel
12.1.8.3. South Africa
12.1.8.4. Rest of MEA
12.1.9. MEA Urothelial Carcinoma Treatment Market - Opportunity Analysis Index, By Therapy, Distribution Channel, and Country, 2017 – 2023
12.1.10. MEA Urothelial Carcinoma Treatment Market Dynamics – Trends
13. COMPETITION LANDSCAPE
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Ferring B.V. (Switzerland)
13.2.2. Azanta A/S (Denmark)
13.2.3. Novartis AG (Switzerland)
13.2.4. GlaxoSmithKline plc (U.K.)
13.2.5. AstraZeneca plc (U.K.)
13.2.6. Pfizer, Inc. (U.S.)
13.2.7. Bayer AG (Germany)
14. RESEARCH METHODOLOGY
15. KEY ASSUMPTIONS AND ACRONYMS
